## Paul Wx Foley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4720773/publications.pdf

Version: 2024-02-01

361045 344852 39 1,606 20 36 citations h-index g-index papers 39 39 39 2196 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. European Journal of Heart Failure, 2019, 21, 998-1007.	2.9	233
2	Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 29.	1.6	190
3	Left Ventricular Midwall Fibrosis as a Predictor of Mortality and Morbidity After Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy. Journal of the American College of Cardiology, 2012, 60, 1659-1667.	1.2	169
4	His bundle pacing, learning curve, procedure characteristics, safety, and feasibility: Insights from a large international observational study. Journal of Cardiovascular Electrophysiology, 2019, 30, 1984-1993.	0.8	125
5	Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 663-670.	3.3	96
6	Cardiac Resynchronization Therapy Delivered Via a Multipolar Left Ventricular Lead is Associated with Reduced Mortality and Elimination of Phrenic Nerve Stimulation: Longâ€Term Followâ€Up from a Multicenter Registry. Journal of Cardiovascular Electrophysiology, 2015, 26, 540-546.	0.8	93
7	Outcomes of Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy. Journal of the American College of Cardiology, 2017, 70, 1216-1227.	1.2	69
8	What is treatment success in cardiac resynchronization therapy?. Europace, 2009, 11, v58-v65.	0.7	61
9	Left ventricular reverse remodelling, longâ€ŧerm clinical outcome, and mode of death after cardiac resynchronization therapy. European Journal of Heart Failure, 2011, 13, 43-51.	2.9	59
10	Incidental cardiac findings on computed tomography imaging of the thorax. BMC Research Notes, 2010, 3, 326.	0.6	50
11	Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. European Heart Journal, 2009, 30, 2749-2757.	1.0	48
12	His Bundle Pacing: A New Strategy for Physiological Ventricular Activation. Journal of the American Heart Association, 2019, 8, e010972.	1.6	48
13	Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPEâ€HF) trial. ESC Heart Failure, 2018, 5, 965-976.	1.4	38
14	Radial dyssynchrony assessed by cardiovascular magnetic resonance in relation to left ventricular function, myocardial scarring and QRS duration in patients with heart failure. Journal of Cardiovascular Magnetic Resonance, 2009, 11, 50.	1.6	34
15	Left ventricular non-compaction: clinical features and cardiovascular magnetic resonance imaging. BMC Cardiovascular Disorders, 2009, 9, 37.	0.7	31
16	Myocardial Fibrosis Predicts Ventricular Arrhythmias and Sudden Death After Cardiac Electronic Device Implantation. Journal of the American College of Cardiology, 2022, 79, 665-678.	1.2	30
17	Cost-Effectiveness Analysis of QuadripolarÂVersus Bipolar Left Ventricular Leads for Cardiac Resynchronization Defibrillator TherapyÂinÂa Large, Multicenter UKÂRegistry. JACC: Clinical Electrophysiology, 2017, 3, 107-116.	1.3	28
18	Realâ€world evidence in a national health service: results of the UK CardioMEMS HF System Postâ€Market Study. ESC Heart Failure, 2022, 9, 48-56.	1.4	28

#	Article	IF	CITATIONS
19	Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance. Journal of Cardiovascular Medicine, 2010, $11$ , $386\text{-}388$ .	0.6	25
20	Fluoroscopic Left Ventricular Lead Position and the Longâ€Term Clinical Outcome of Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 785-797.	0.5	24
21	Multicenter Randomized Controlled Crossover Trial Comparing Hemodynamic Optimization Against Echocardiographic Optimization of AVÂand VV Delay of Cardiac Resynchronization Therapy. JACC: Cardiovascular Imaging, 2019, 12, 1407-1416.	2.3	20
22	A user-centred home monitoring and self-management system for patients with heart failure: a multicentre cohort study. European Heart Journal Quality of Care & Dinical Outcomes, 2015, 1, 66-71.	1.8	18
23	Cardiac Resynchronization Therapy in Patients with Mildly Impaired Left Ventricular Function. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S186-S189.	0.5	16
24	The Benefits of Using a Bismuth ontaining, Radiationâ€Absorbing Drape in Cardiac Resynchronization Implant Procedures. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 828-833.	0.5	12
25	Amiodaroneâ€"Avoid the danger of Torsade de Pointes. Resuscitation, 2008, 76, 137-141.	1.3	11
26	Implantable Cardioverter Defibrillator Therapy for Primary Prevention of Sudden Cardiac Death after Myocardial Infarction:. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S131-S134.	0.5	10
27	Effects of cardiac resynchronization therapy in patients unselected for mechanical dyssynchrony. International Journal of Cardiology, 2010, 143, 51-56.	0.8	10
28	A retrospective study of the management of retro-peritoneal bleeding after percutaneous coronary intervention in the era of combination anti-platelet therapy. Journal of Cardiovascular Medicine, 2008, 9, 56-58.	0.6	8
29	Inter―and Intravein Differences in Cardiac Output with Cardiac Resynchronization Pacing using a Multipolar LV Pacing Lead. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 267-274.	0.5	5
30	Renal function and the longâ€term clinical outcomes of cardiac resynchronization therapy with or without defibrillation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 595-602.	0.5	5
31	Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of atrio-ventricular junction ablation in patients with permanent atrial fibrillation. European Heart Journal, 2008, 29, 2182-2182.	1.0	4
32	Asystole and scarring of the interventricular septum in hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 2009, 10, 349-351.	0.6	3
33	Should Patients With Atherosclerosis or Peripheral Vascular Disease Be Stratified for Factor V Leiden?. Blood, 1997, 90, 2114-2114.	0.6	2
34	Extensive venous thrombosis and cardiomyopathy demonstrated with cardiovascular magnetic resonance. Journal of Cardiovascular Medicine, 2008, 9, 1075-1077.	0.6	1
35	Ivabradine – well tolerated in elderly patients with systolic heart failure. International Journal of Cardiology, 2017, 249, 330-331.	0.8	1
36	Life threatening polyserositis post oesophagectomy. Respiratory Medicine Case Reports, 2019, 26, 42-44.	0.2	1

#	Article	IF	CITATIONS
37	Left atrial appendage thrombus revealed by 16-slice cardiac computerized tomography. Journal of Cardiovascular Medicine, 2006, 7, 454-455.	0.6	O
38	Constrictive pericarditis as a late sequela of streptococcal pneumonia. Journal of Cardiovascular Medicine, 2012, 13, 839-841.	0.6	0
39	89â€Implementation of a Modified Version of Nice Clinical Guideline 95 On Chest Pain of Recent Onset: Experience in a District General Hospital. Heart, 2016, 102, A63-A64.	1.2	O